Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Research output: Contribution to journalJournal articleResearchpeer-review

  1. ERG Controls B Cell Development by Promoting Igh V-to-DJ Recombination

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Single mRNP Analysis Reveals that Small Cytoplasmic mRNP Granules Represent mRNA Singletons

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Nodal Signaling Regulates Germ Cell Development and Establishment of Seminiferous Cords in the Human Fetal Testis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Gamma-Aminobutyric Acid Signaling in Brown Adipose Tissue Promotes Systemic Metabolic Derangement in Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Endoskopisk behandling af hydrocefalus

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dulaglutide for erectile dysfunction in type 2 diabetes

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.

Original languageEnglish
JournalCell Reports
Volume1
Issue number1
Pages (from-to)100006
DOIs
Publication statusPublished - 21 Apr 2020

ID: 61308830